BSX Q2 Deep Dive: Cardiovascular Momentum, New Technologies, and Global Expansion Shape Outlook

Medical device company Boston Scientific (NYSE:BSX) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 22.8% year on year to $5.06 billion. Guidance for next quarter’s revenue was optimistic at $4.97 billion at the midpoint, 2.2% above analysts’ estimates. Its non-GAAP profit of $0.75 per share was 4.1% above analysts’ consensus estimates.

Is now the time to buy BSX? Find out in our full research report (it’s free).

StockStory’s Take

Boston Scientific’s second quarter results reflected broad-based strength, with operational sales rising sharply and organic growth notably outpacing the company’s underlying market rates. Management attributed the quarter’s outperformance to the Cardiovascular segment, particularly the rapid adoption of FARAPULSE for atrial fibrillation and the sustained momentum of the WATCHMAN device. CEO Michael Mahoney highlighted that the “reliability and trust that the physician community and referring physicians have in [WATCHMAN], along with our clinical and sales team, is driving that.” The company also cited double-digit growth in several international markets and ongoing commercial execution as key contributors to strong top-line and adjusted profitability.

Looking ahead, Boston Scientific’s updated guidance is grounded in expectations for continued expansion in core cardiovascular therapies, additional product launches, and further international market penetration. Management emphasized that ongoing investments in research and development, as well as anticipated regulatory approvals for devices such as the EMPOWER leadless pacemaker and expanded indications for FARAPULSE, are set to support the company’s growth trajectory. CFO Jonathan Monson stated, “We now expect to expand full year adjusted operating margin by 75 to 100 basis points while increasing our level of investment in R&D to fuel durable, differentiated revenue growth.”

Key Insights from Management’s Remarks

Management pointed to product innovation and market adoption in cardiovascular therapies as the primary drivers of recent performance, while also addressing operational challenges from product discontinuations and tariffs.

• Cardiovascular growth surge: The Cardiovascular segment led company growth, fueled by strong demand for FARAPULSE (a pulsed field ablation system for atrial fibrillation) and robust performance of the WATCHMAN left atrial appendage closure device. New labeling and expanded indications, particularly in Japan and the U.S., supported broader adoption.

• WATCHMAN and concomitant procedures: WATCHMAN’s uptake was enhanced by the trend toward concomitant procedures, where atrial fibrillation ablation and appendage closure are performed together. Over 60% of U.S. electrophysiologists using WATCHMAN are adopting this approach, following recent clinical data and reimbursement changes. Management expects ongoing growth as clinical evidence and payer support evolve.

• Impact of product discontinuation: The global discontinuation of the ACURATE valve led to inventory write-downs and pressured gross margins. However, management highlighted that strong revenue growth and “spend control” offset these headwinds, keeping full-year margin guidance intact.

• Geographic diversification: The Asia Pacific region posted double-digit growth, led by Japan and China, where new product launches and expanded clinical indications contributed. The company expects mid-teens growth in China to continue, citing the diversification of its portfolio and ongoing investment in commercial capabilities.

• Strategic acquisitions: Recent acquisitions of SoniVie (ultrasound-based therapy for hypertension) and Intera Oncology (liver cancer therapies) are intended to strengthen the company’s portfolio in targeted adjacencies. Management noted that these additions align with Boston Scientific’s strategy to address large, growing end markets and complement existing franchises.

Drivers of Future Performance

Boston Scientific’s forward outlook is anchored by continued innovation, expanded product approvals, and a focus on international growth, balanced against expected tariff and reimbursement headwinds.

• Expanded product indications: Management anticipates growth from regulatory approvals for new devices and expanded indications, including the expected launch of the EMPOWER leadless pacemaker and additional labeling for FARAPULSE in Japan and China. These approvals are seen as key to increasing the company’s addressable market and supporting durable revenue growth.

• Ongoing R&D and investment: The company plans to maintain elevated investment in research and development, particularly to accelerate clinical trials and support upcoming product launches. This includes expanding clinical evidence for products such as FARAPULSE and WATCHMAN, which management believes will reinforce competitive positioning.

• External pressures and risk management: Tariffs and reimbursement changes—such as proposed cuts to Medicare payments for certain cardiac procedures—present headwinds. Management stated that they expect a $100 million tariff headwind for the year but intend to offset these impacts through sales mix improvements and expense discipline. They also acknowledged the need for ongoing engagement with medical societies to address reimbursement challenges.

Catalysts in Upcoming Quarters

Looking ahead, the StockStory team will focus on (1) the pace and commercial impact of new product launches and regulatory approvals, (2) the sustainability of double-digit growth in key international markets such as China and Japan, and (3) the company’s ability to manage margin pressures from tariffs and reimbursement changes. Progress in integrating recent acquisitions and execution on clinical trial milestones will also be important indicators.

Boston Scientific currently trades at $108.70, up from $103.22 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).

Our Favorite Stocks Right Now

When Trump unveiled his aggressive tariff plan in April 2024, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses.

Don’t let fear keep you from great opportunities and take a look at Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.